RET and non-small cell lung carcinoma: Due to the structurally high similarity of RET and VEGFR2 ATP binding sites,3 several multikinase inhibitors (MKIs) have been tried for RET fusion NSCLC, such as cabozantinib, vandetanib, lenvatinib, and alectinib.